Skip to main content

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

Trial Status: Active

This is a randomized, double-blind, multicenter, global Phase 3 study to assess the efficacy and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in patients with recurrent or metastatic head and neck cancer.

Inclusion Criteria

  • Are aged 18 years and over
  • Recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), (oral cavity, oropharynx, hypopharynx, or larynx) which has progressed on or after previous systemic cancer therapy and is not amenable to curative therapy
  • Received prior treatment using a PD-(L)1 inhibitor
  • Prior platinum failure
  • Received 1 or 2 prior systemic regimens for recurrent or metastatic SCCHN
  • Has measurable disease per RECIST 1.1
  • A fresh or recently acquired tumor tissue for the purpose of biomarker testing
  • World Health Organization (WHO)/ Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

Exclusion Criteria

  • Head and neck cancer of any primary anatomic location in the head and neck not specified in the inclusion criteria, including participants with SCCHN of unknown primary or non-squamous histologies
  • Had prior cetuximab therapy (unless it was administered in curative locally advanced setting with radiotherapy and no disease progression for at least 6 months following the last cetuximab dose)
  • Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis
  • Any concurrent anticancer treatment, except for hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy)


San Francisco
University of California San Francisco
Status: ACTIVE
Contact: UCSF Clinical Trials
Phone: 877-827-3222


Brigham and Women's Hospital
Status: ACTIVE
Dana-Farber Cancer Institute
Status: ACTIVE


Ohio State University Comprehensive Cancer Center


University of Pennsylvania / Abramson Cancer Center
Status: ACTIVE


M D Anderson Cancer Center

Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)

who had prior immune checkpoint inhibitor and platinum-based chemotherapy treatment will be

randomized in a 2:1 ratio to monalizumab and cetuximab or placebo and cetuximab. Efficacy and

safety assessments will be performed periodically from the time of enrollment and throughout

the study. Patients in all arms will continue therapy until progression, unacceptable

toxicity, withdrawal of consent, or another discontinuation criterion is met. All patients

will be followed for survival after progression is confirmed.

Trial Phase Phase III

Trial Type Treatment

Lead Organization
AstraZeneca Pharmaceuticals LP

  • Primary ID D7310C00001
  • Secondary IDs NCI-2020-13276
  • ID NCT04590963